All Type of News
Novacell Technology develops novel biomarker that may accurately diagnose breast cancer
Novacell Technology said yesterday it has created a new biomarker NCB102 that is considered to a highly accurate method of obtaining a preoperative histological diagnosis of breast cancer showing a resistance to Roche...
Xolair significantly improves itch in patients with severe form of chronic skin disease CSU, NovartiXolar (omalizumab) was showed to be effective, safe and well tolerated in refractory refractory chronic spontaneous urticarial (CSU) patients, including those on antihistamines ...
|
Effectiveness and cost-effectiveness of Crestor 5 mg are verified, AstraZeneca Korea says
In the previous clinical trial of 1,851 Korean patients with dyslipidemia, Crestor 5 mg (rosuvastatin) is more effective and cost-effective in lowering low-density lipoprotein cholesterol (LDL-C) and in attainment of ...
Small drugmakers still scramble to survive
Despite the recent report that revenues and operating profits of major drug companies surged 4.5 percent and 40 percent on-year, respectively, in the first half of this year, mid- or small-sized firms are seeking ways...
Wholesalers’ warehouse provision stirs confusion
A conflict is still arising from a changed law requiring a drug wholesaler to have a warehouse size of at least 80 pyung (1 pyung equals to 3.3 square meters).
The law will take effect from April next year. The gov...
Samchundang Pharm shortens acquisition date of DHP Korea
Samchung Pharm plans to shorten the acquisition date of DHP Korea from Nov. 20 to Nov. 12 in a bid to ensure better liquid assets, map-out of new facility investment and maximization of shareholders’ value, the compan...
Ildong Pharm obtains U.S. patent on production of calcitriol or calcifediol
Ilodng Pharm said on Aug. 14 that it has obtained an U.S. patent on a buffer composition for promoting production of calcitriol or calcifediol.
The title of this patent is a buffer composition for promoting product...
Drugmakers fare well in first half
Local pharmaceutical firms posted sound sales and earnings in the first half of this year on the back of solid demand, data showed Monday, while they suffered some setbacks due to the government-mandated price cuts of...
Leading drug makers’ outpatient sales drop in July
Korea's ten leading companies saw their outpatient sales decline in July from a year earlier, data showed Monday.
According to the data by Shinhan Investment Corp., outpatient sales by the ten companies stood at 20...
Viread takes on Baraclude
Yuhan Corp. is enjoying brisk sales of its new anti-hepatitis B drug, Viread (tenofovir) developed by Gilead Sciences as a nucleotide reverse transcriptase inhibitor.
According to IMS data, sales of Viread reached ...
